Lymphatic filariasis is one of the 20 diverse neglected tropical diseases (NTD) affecting more than 120 million people in 72 countries in Asia, Africa, the Western Pacific, parts of the Caribbean, and South America.
People living with lymphatic filariasis (LF), commonly known as elephantiasis, are often stigmatized due to the visible and disfiguring symptoms of the disease. LF is a parasitic infection transmitted by mosquitoes and can lead to severe swelling and enlargement of the limbs, genitals, and breasts.
The visible symptoms of the disease can lead to social exclusion and discrimination, with affected individuals often being shunned by their communities and even their families. The stigma associated with elephantiasis can also impact mental health, with affected individuals experiencing depression, anxiety, and feelings of shame and isolation.
Brugia Rapid point-of-care cassette test manufactured by Reszon Diagnostics is recommended by WHO for use during Transmission Assessment Surveys (TAS) to detect IgG4 antibody against Brugia spp. in human blood samples. Through the use of our product as diagnostic tool, we hope that the correct intervention can be administered and hence helping to stop the spread of filariasis infection in the affected countries.
WHO (2023) “People living with Elephantiatis are often stigmatized” – patient | WHO | Regional Office for Africa. Accessed on 6 Mar 2023